Metastases Spinal Tumor Market Research Report - Forecast till 2027

Metastases Spinal Tumor Market information: by type (extradural, and others), Diagnosis (laboratory tests, imaging tests, biopsy, and others), Treatment (non- operative treatment, surgical treatment, and others), End user- Forecast till 2027

ID: MRFR/Pharma/2752-HCR | February 2021 | Region: Global | 80 pages

Metastases Spinal Tumor Market Scenario


Metastases spinal tumor is one of the most common problems in oncology. Approximately 5%-10% of the cancer patients face spinal metastases disease. Most of the metastatic spinal tumors are developed outside the dura (extradural). Around 70% of the spine tumors occur in the thoracic region, while 20% in the lumbar, and 10% in the neck region. Some of the common symptoms of metastases spinal tumor are back pain, tingling or numbness, and weakness.


Early diagnosis can provide better treatment management of this disorder. Major diagnostic solution provider companies are engaged in developing and launching new medical imaging devices. Introduction and rapid adoption of advanced diagnostic devices are driving the metastases spinal tumor market growth. Increasing research, clinical trials, and new solution development in the field of oncology drive the metastases spinal tumor market. Additionally, growing demand for diagnostic devices and treatment from emerging markets of Asia and Latin America add fuel to the growth of the metastases spinal tumor market.


The metastases spinal tumor market is expected to grow at the CAGR of ~3.2% during the forecast period and is estimated to reach USD 1547.8 million by 2023.


FIGURE 1 Global metastases spinal tumor market share by type 2016 (%)


 


Sources: National Center for Biotechnology Information (NCBI), Cancer Australia, the American Society of Neuroradiology, Directorate of Industries, annual report, white paper, company presentation


Intended Audience



  • Metastases Spinal Tumor Diagnostic and Treatment Supplies Companies

  • Metastases Spinal Tumor Diagnostic and Treatment Supplies Providers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Segments                                                                                                                                         
The metastases spinal tumor market is segmented on the basis of type, which comprise extradural, metastatic spinal tumors of the bone, and others.


On the basis of diagnosis, metastases spinal tumor market is segmented into laboratory tests, imaging tests, biopsy, and others. Imaging tests includes X-Ray, Computed Tomography (CT scan), Magnetic Resonance Imaging (MRI scan), Angiography, F-18 fluorodeoxyglucose positron emission tomography, and others. Biopsy is sub-segmented into percutaneous needle biopsy, open incisional and excisional biopsy, and others.


On the basis of treatments, the metastases spinal tumor market is segmented into non-operative treatment, surgical treatment, and others. Non operative treatment is sub-segmented into medications, radiation therapy, ablation, chemotherapy, and others. Medications includes anti-inflammatory drugs, narcotics (opioids), corticosteroids, rankl inhibitors and bisphosphonates, and others. Ablation is further sub-segmented into radiofrequency ablation, cryoablation, and others. Surgical treatment is further sub-segmented into minimally invasive surgery, open surgery, and others. Minimally invasive surgery is sub-segmented into vertebral fracture treatments, transarterial chemoembolization, and others. Vertebral fracture treatments is further sub-segmented into vertebroplasty, kyphoplasty (vertebral augmentation), and others. Open surgery includes spinal stabilization surgery, spinal decompression surgery, and others.


On the basis of end user, metastases spinal tumor market is segmented into hospitals & clinics, ambulatory surgery centers, academic institutes, research centers, and others.


Research Methodology

Sources: National Center for Biotechnology Information (NCBI), Cancer Australia, the American Society of Neuroradiology, Directorate of Industries, annual report, white paper, company presentation

Regional Analysis of the Metastases Spinal Tumor Market  
     
          
The Americas
dominate the metastases spinal tumor market. An spinal tumor is a severe medical problem in Americas. North American countries such as the US and Canada dominate the market, while, Latin America region is also growing significantly. Due to highly advance medical facilities, focus on research and clinical trials, and upcoming healthcare bill, the US is expected to remain top revenue generating country in the global metastases spinal tumor treatment. Increasing number of patients with metastases spinal tumor is one of the major drivers for the Latin American market.


Europe is the second largest market for metastases spinal tumor treatment. This region is mainly divided into Eastern Europe and Western Europe. The West European countries dominate this market while East European countries also show significant growth. Increasing prevalence of spinal tumor is primarily driving the market growth.  Furthermore, some other factors such as availability of advanced healthcare facilities and high expenditure on the health care are driving the growth of the metastases spinal tumor market.


Asia Pacific region is one of the high potential markets in the healthcare sector. This region is showing exceptional growth in almost every product and services mainly related to medical field owing to  rising middle-class population and their spending on healthcare and related services. Additionally, increasing awareness about the disease drives the growth of the metastases spinal tumor market. The Governments of different countries are  focusing on improvement of public health by providing the subsidy for affordable healthcare as well as running awareness campaign, which, in turn, leads the growth of the metastases spinal tumor market. Some other factors such as increasing cases of metastases spinal tumor, improving healthcare infrastructure, and availability of affordable healthcare facilities are also boosting the market growth. Owing to availability of the cost-effective healthcare facilities, patients from various high-income nations are flying to get affordable treatments, which, in turn, boost the medical tourism in this region.


Lack of awareness about the disorder and limited availability of required healthcare facilities are major restraints for the Middle East & Africa metastases spinal tumor market.


Key Players in the Metastases spinal tumor Market   
 
                
Some of the key players in this market: F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (US), Novartis AG(Switzerland), Abbott (US), Beckman Coulter Inc. (US), Debiopharm Group (Switzerland), AbbVie Inc. (US), Bayer AG (Germany), and others.



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 1547.8 Million
  • 2027: Significant Value
  •   CAGR   3.2% (2016-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Diagnosis, Treatment, End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (US), Novartis AG(Switzerland), Abbott (US), Beckman Coulter Inc. (US), Debiopharm Group (Switzerland), AbbVie Inc. (US), Bayer AG (Germany), and others
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Introduction and rapid adoption of advanced diagnostic devices
  • Increasing research
  • Clinical trials
  • New solution development in the field of oncology


  • 1. Report Prologue

    2. Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    2.3 Market Structure

    2.4. Market Segmentation

    3. Research Methodology

    3.1 Research Process

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    3.5 Forecast Model

    4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Mega Trends

    4.5 Macroeconomic Indicators

    5. Market Factor analysis

    5.1 Value Chain Analysis

    5.2 Porters Five Forces Analysis

    5.3 Demand & Supply: Gap Analysis

    5.4 Pricing analysis

    5.5 Investment Opportunity Analysis

    5.6 Merger and Acquisition landscape

    5.7 Upcoming Trends

    6. Global Metastases spinal tumor Market by Type

    6.1 Extradural

    6.2 Metastatic Spinal Tumors of the Bone

    6.3 Others

    7. Global Metastases spinal tumor Market by Diagnosis

    7.1 Metastatic Spinal Tumors of the Bone

    7.2 Imaging tests

    7.1.1 X-Ray

    7.1.2 Computed Tomography (CT scan)

    7.1.3 Magnetic Resonance Imaging (MRI scan)

    7.1.4 Angiography

    7.1.5 F-18 fluorodeoxyglucose positron emission tomography

    7.1.6 Others

    7.3 Biopsy

    7.3.1 Percutaneous Needle Biopsy

    7.3.2 Open Incisional and Excisional Biopsy

    7.3.3 Others

    7.4 Others

    8. Global Metastases spinal tumor Market by Treatment

    8.1 Non operative treatment

    8.1.1 Medications

    8.1.1.1 Anti-inflammatory drugs

    8.1.1.2 Narcotics (opioids), Corticosteroids

    8.1.1.3 RANKL inhibitors and bisphosphonates

    8.1.1.4 Others

    8.1.2 Radiation Therapy

    8.1.3 Ablation

    8.1.3.1 Radiofrequency ablation

    8.1.3.2 Cryoablation

    8.1.3.3 Others

    8.1.4 Chemotherapy

    8.1.5 Others

    8.2 Surgical treatment

    8.2.1 Minimally Invasive Surgery

    8.2.1.1 Vertebral Fracture Treatments

    8.2.1.1.1 Vertebroplasty

    8.2.1.1.2 Kyphoplasty (Vertebral Augmentation)

    8.2.1.1.3 Others

    8.2.1.2 Transarterial Chemoembolization

    8.2.1.3 Others

    8.2.2 Open Surgery

    8.2.2.1 Spinal Stabilization Surgery

    8.2.2.2 Spinal Decompression Surgery

    8.2.2.3 Others

    8.2.3 Others

    8.3 Others

    9. Global Metastases spinal tumor Market by End User

    9.1 Hospital and clinics

    9.2 Ambulatory surgery centers

    9.3 Academic institutes

    9.4 Research centers

    9.5 Others

    10. Global Metastases spinal tumor Market by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 The US

    10.2.1.2 Canada

    10.2.2 Latin America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia

    10.4.1 China

    10.4.2 India

    10.4.3 Japan

    10.4.4 South Korea

    10.4.5 Rest of Asia

    10.5 Pacific

    10.6 Middle East & Africa

    10.6.1 UAE

    10.6.2 Saudi Arabia

    10.6.3 Egypt

    10.6.4 Rest of the Middle East & Africa

    11. Competitive Landscape

    12. Company Profile

    13. Conclusion

    13.1 Key findings

    13.1.1 From CEO’s viewpoint

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Metastases Spinal Tumor Market

    14. Appendix